“We are pleased that this transaction has been finalized, and we renew our commitment to allergy immunotherapy, our customers and their patients, ensuring that we will continue to deliver quality allergy immunotherapy products, services and customer support,” shares John G. Roby, GREER President and CEO.
GREER’s clinical development programs are focused on the company’s investigational sublingual allergy immunotherapy liquid (SAIL™). The company recently completed a successful Phase III study evaluating the efficacy and safety of GREER® SAIL™ as a treatment for adults with short ragweed allergies. Sublingual allergy immunotherapy (SLIT) is a method of allergy immunotherapy that delivers the same liquid allergenic extract approved for subcutaneous injections, but it is administered under the tongue. SLIT has been widely accepted as a safe, effective treatment for allergic rhinitis in Europe for years.1 However, SLIT is currently investigational in the United States.